Abstract
Long non-coding RNAs (lncRNAs) are functionally versatile molecules that regulate gene expression at all levels of biological organization. RNA modulation, at the moment, has emerged as a powerful therapeutic technique to treat human diseases. Lately, lncRNAs have been acknowledged as key players in human metabolism and, indeed, implicated in the etiology of many common diseases other than cancers, where they can perhaps serve as reliable markers to determine disease status or assess outcomes of an intervention. Here, in this review, we cite examples of such lncRNAs, discuss their mechanistic role in human diseases and their genetic association, quote potential biomarkers found in human blood, summarize the methods for therapeutic targeting lncRNAs and examine the progress of lncRNA based drugs in clinical trials. Thus, we propose that lncRNAs serve as both a biomarker and an effective therapeutic target with promising clinical utility to manage human metabolic diseases.
Keywords: Epigenetics, lncRNAs, RNA therapeutics, type 2 diabetes, obesity, cardiovascular disease, neurological disease, human metabolism.
Current Pharmaceutical Design
Title:Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Volume: 27 Issue: 35
Author(s): Khushdeep Bandesh , Daisy Masih , Nirjhar Bhattacharyya and Dwaipayan Bharadwaj *
Affiliation:
- Systems Genomics Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi-110067,India
Keywords: Epigenetics, lncRNAs, RNA therapeutics, type 2 diabetes, obesity, cardiovascular disease, neurological disease, human metabolism.
Abstract: Long non-coding RNAs (lncRNAs) are functionally versatile molecules that regulate gene expression at all levels of biological organization. RNA modulation, at the moment, has emerged as a powerful therapeutic technique to treat human diseases. Lately, lncRNAs have been acknowledged as key players in human metabolism and, indeed, implicated in the etiology of many common diseases other than cancers, where they can perhaps serve as reliable markers to determine disease status or assess outcomes of an intervention. Here, in this review, we cite examples of such lncRNAs, discuss their mechanistic role in human diseases and their genetic association, quote potential biomarkers found in human blood, summarize the methods for therapeutic targeting lncRNAs and examine the progress of lncRNA based drugs in clinical trials. Thus, we propose that lncRNAs serve as both a biomarker and an effective therapeutic target with promising clinical utility to manage human metabolic diseases.
Export Options
About this article
Cite this article as:
Bandesh Khushdeep , Masih Daisy , Bhattacharyya Nirjhar and Bharadwaj Dwaipayan *, Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases, Current Pharmaceutical Design 2021; 27 (35) . https://dx.doi.org/10.2174/1381612827666210315145254
DOI https://dx.doi.org/10.2174/1381612827666210315145254 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Insights into Complex Cardiovascular Pathologies using 4D Flow Analysis by Cardiovascular Magnetic Resonance Imaging
Current Pharmaceutical Design Engineering Three-Dimensional Cardiac Microtissues for Potential Drug Screening Applications
Current Medicinal Chemistry Heart Failure in North America
Current Cardiology Reviews Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review
Current Neuropharmacology Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Puerarin: A Review on the Pharmacological Activity, Chemical Properties and Pharmacokinetics of Main Isoflavonoid
The Natural Products Journal Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Current Pharmaceutical Design New Targeted Therapies for Thyroid Cancer
Current Genomics Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients
Current Pharmaceutical Design A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus
Current Diabetes Reviews Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure
Current Cardiology Reviews Altered Calmodulin Degradation and Signaling in Non-Neuronal Cells from Alzheimer’s Disease Patients
Current Alzheimer Research Sudden Infant Death Syndrome from Epidemiology to Pathophysiology
Current Pediatric Reviews Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews Incremental Value of Two Dimensional Speckle Tracking Echocardiography in the Functional Assessment and Characterization of Subclinical Left Ventricular Dysfunction
Current Cardiology Reviews Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy